Table 3.

Secondary endpoints at baseline and 7 years follow‐up expressed as mean (SD) and median (range)

	Total patient group	Patients receiving Bulkamid as a primary treatment	Patients receiving Bulkamid as a secondary treatment
	(n = 388)	(n = 261)	(n = 127)
Pad usage
Baseline	4.3 (2.3); 4.0 (1.0–15.0)	4.2 (2.3); 4.0 (1.0–15.0)	4.4 (2.4); 4.0 (1.0–14.0)
7 years	1.9 (1.7); 1.0 (0–9.0)	1.8 (1.7); 1.0 (0–9.0)	2.0 (1.7); 2.0 (0–9.0)
VAS QoL
Baseline	7.9 (1.7); 8.0 (2.0–10.0)	7.8 (1.8); 8.0 (2.0–10.0)	8.0 (1.6); 8.0 (2.0–10.0)
7 years	3.5 (2.2); 3.0 (1.0–10.0)	3.5 (2.2); 3.0 (1.0–10.0)	3.5 (2.1); 3.0 (1.0–10.0)
ICIQ‐UI SF
Baseline	15.5 (2.5); 16.0 (5.0–21.0)	15.2 (2.4); 15.0 (5.0–21.0)	16.1 (2.6); 16.0 (10.0–21.0)
7 years	7.1 (5.4); 8.0 (0–20.0)	6.6 (5.3); 7.0 (0–19.0)	8.0 (5.4); 9.0 (0–20.0)

Note: All results were statistical significant with p < .0001.

Abbreviations: ICIQ‐UI SF, International Consultation on Incontinence Questionnaire‐Short Form; VAS QoL, Visual Analog Scale Quality of Life.